| IN TR ODUC TION
Hyperphosphatemia is a well-documented sequela of chronic kidney disease (CKD) in cats, [1] [2] [3] [4] [5] and associated with increased risks for death and progression of azotemia. [6] [7] [8] Actions of the body to maintain normophosphatemia result in secondary renal hyperparathyroidism and fibroblast growth factor 23 (FGF23) excess. 9 These hormonal derangements prevent overt hyperphosphatemia in the early stages of CKD, 10 but contribute to bone pathology and soft tissue calcification. 9, 11, 12 The systemic condition of disturbed mineral metabolism, bone disease, and extraskeletal calcification caused by CKD has been termed CKDmineral and bone disorder (CKD-MBD). 9, 11, 13 Dietary phosphate restriction is the mainstay of management of CKD-MBD in cats, and has been shown to reduce plasma phosphate, FGF23, and PTH concentrations, and to improve survival. [14] [15] [16] [17] [18] Recently, there is increased interest in the role of magnesium in human CKD-MBD. Magnesium is an essential mineral for numerous intracellular processes, 19 but also an inhibitor of vascular calcification [20] [21] [22] and the release of profibrotic cytokines. 23 Hypomagnesemia is a risk factor for death, [24] [25] [26] [27] [28] and possibly for kidney function decline in human CKD patients. 23, 24 Magnesium furthermore appears to modify the risks associated with hyperphosphatemia in humans with CKD, as high phosphate was only associated with higher risks of death 27 and progression to end-stage renal disease 23 in patients with lower serum total magnesium concentrations (tMg). Interestingly, magnesium might be involved in FGF23 regulation, because an inverse association between these two variables was observed in human CKD patients on hemodialysis, 29 and serum FGF23 concentrations were increased in rodents fed a magnesium deficient diet. 30, 31 Plasma FGF23 itself is a strong predictor of survival and progression in cats with CKD. 5 Little is known about the role of magnesium in feline CKD-MBD.
A study among cats found significantly increased plasma tMg in endstage CKD, whilst low plasma tMg was observed in up to 25% of cats with earlier stages of CKD. 3 Neither the prognostic significance of magnesium status, nor the relationship between plasma tMg and FGF23 have been examined in cats with CKD. Therefore, we aimed to explore, first, the prevalence and risk factors for magnesium disorders in cats with azotemic CKD, second, the relationship of plasma tMg with FGF23 and other clinicopathological variables, and third, the prognostic significance of magnesium disorders for all-cause mortality and renal function decline in a cohort of cats with azotemic CKD.
| M E TH O DS

| Case selection
Cats were identified from the clinical records of two first opinion prac- 
| Data collection
assays, respectively. For measurement of FGF23, samples were diluted with the zero standard to achieve a reading on the standard curve. The PTH assay had a limit of detection of 5.2 pg/mL, 32 Data on muscle mass score (n 5 68), ionized calcium and venous blood gases (n 5 47), and vitamin D-metabolites (n 5 17) were available in <50% of cats, therefore these variables were excluded from analysis.
| Prevalence and factors associated with magnesium disorders
Cats with azotemic CKD were categorized in 3 groups based on the lower and upper limits of the reference interval for plasma tMg derived from apparently healthy cats 9 years old, which was calculated using the parametric method (ie, mean 6 2SD), and baseline characteristics among the 3 magnesium groups compared. Binary logistic regression was performed to explore risk factors for hypomagnesemia or hypermagnesemia, with normomagnesemic cats as controls. Plasma FGF23
and PTH were log-transformed before analysis (logarithmus naturalis
[ln]). Variables significantly associated with these disorders (P < . 
| Association of plasma total magnesium with survival
To assess if plasma tMg was related to survival, all cats were included in a survival analysis for which the date of diagnosis of azotemic CKD was designated as baseline, death of all-causes was the event of interest, and censoring occurred for cats that were lost to follow-up or that were still alive on July 1, 2016. Cats lost to follow-up were censored on the last date they were known to be alive. 
| Interaction between phosphate and magnesium
| Plasma total magnesium in cats with azotemic CKD
Between August 1999 and July 2013, a total of 517 cats were diagnosed with azotemic CKD, of which 96 cats were excluded for the following reasons: concurrent hyperthyroidism (n 5 79), not meeting the study criteria for diagnosis of CKD (n 5 16), or prednisolone administration (n 5 1). Of the 421 eligible cats, 88 cats had no residual plasma Abbreviations: PCV, packed cell volume; SBP, systolic blood pressure; USG, urine specific gravity.
sample available for measurement of tMg, 157 cats lacked baseline information on plasma FGF23 concentration, and 2 samples were grossly hemolyzed. Thus, 174 cats were enrolled in our study, some of which had been included in previous studies. 5, 8 No significant differences were observed between baseline characteristics of the 174 included cats and of the 247 eligible cats that were excluded from analysis because of lack of a residual plasma sample or plasma FGF23 measurement (data not shown).
The study population consisted of 88 females (1 entire) and 86 males (3 entire). Domestic shorthair was the most common breed (n 5 127), followed by domestic longhair (n 5 20), Persian (n 5 10), Burmese (n 5 7), British shorthair (n 5 2), Siamese (n 5 2), and 1 each 
| Prevalence and factors associated with magnesium disorders
The median plasma tMg of the study population was 2. Table 2 . Risk factors associated with magnesium disorders can be found in Table 3 . Hypermagnesemia was predominantly observed in cats with IRIS stage 4 ( Figure 1 ), but no multivariable analysis was performed because of the relatively low number of cases. progressive CKD in the final logistic regression model (Nagelkerke R 2 , .21; Table 6 ).
| Interaction between phosphate and magnesium
In the subgroup analysis of NP and HP cats (based on IRIS targets for plasma phosphate for each stage) with IRIS stage 2 and 3 CKD, plasma FGF23 concentration was significantly higher in cats with lower plasma tMg compared to cats with higher plasma tMg (Figure 4) 
| D ISC USSION
Results from our observational cohort demonstrate an inverse relationship between plasma tMg and plasma FGF23 concentrations in cats with azotemic CKD. A significant independent association between hypomagnesemia and increased risk of death was observed. Insufficient evidence was found for an independent association between magnesium status and risk of progressive CKD. In additional analyses, the risk of death associated with hyperphosphatemia appeared mitigated by higher plasma tMg, and a possible link between hypomagnesemia and systemic hypertension was identified.
Hypomagnesemia in CKD is thought to be secondary to impaired intestinal absorption or increased renal excretion of magnesium, with depletion of bone and muscle reserves, 34-37 whilst hypermagnesemia results from incapacity of the kidneys to filter sufficient magnesium. 37, 38 Hypermagnesemia was found mostly in cats with severe renal dysfunction in our study (5 of 10 cats with IRIS Stage 4 CKD), and the distribution of magnesium disorders across the different stages of CKD was comparable to those reported before in a smaller number of cats. 3 However, the prevalences of hypomagnesemia and hypermagnesemia were possibly underestimated in our study, because these frequencies were assessed on a single time point rather than in a given time interval, whilst cats with these disorders were characterized by higher risks of death. Missing information on muscle mass necessitated IRIS stage classification based solely on plasma creatinine concentration, and consequently the severity of CKD could have been underestimated in some cats.
Hypomagnesemia was independently associated with systemic hypertension in cats, a relationship that is well-known in human medicine. 36, [39] [40] [41] [42] [43] [44] Magnesium plays an active role in vascular resistance via various mechanisms such as regulation of intracellular calcium concentration, nitric oxide production, and vascular calcification, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and in dogs a decrease in vascular resistance and SBP was observed after magnesium infusion. 55 The difference in plasma tMg between normotensive cats and cats with a (previous) diagnosis of systemic hypertension, however, was small, and therefore not directly clinically relevant.
Increased plasma aldosterone is commonly observed in azotemic cats with systemic hypertension and not influenced by treatment with amlodipine besylate. 56, 57 It could be a possible link between hypomagnesemia and hypertension, because aldosterone stimulates urinary magnesium excretion 58, 59 whilst magnesium inhibits aldosterone release. 60, 61 No information on plasma aldosterone concentration was available for cats included in our study.
An inverse association of plasma tMg with FGF23 was found in our population of cats with CKD, and has previously been identified in human CKD patients on hemodialysis. 29 Rodent studies suggest that circulating FGF23 is influenced by dietary magnesium intake, 30, 31, 62 and lower serum FGF23 concentrations were observed in hemodialysis-patients receiving magnesium-containing laxatives or phosphate binders in comparison to patients not receiving PO magnesium. 29, 63 However, no significant reduction in FGF23 concentration was reported in a study examining the effect of oral magnesium supplementation on serum calcification propensity in human CKD stage 3 and 4 patients. 64 The underlying mechanisms of the relationship between magnesium and FGF23 remain to be elucidated, but it could be hypothesized that FGF23 has an effect on renal magnesium handling, as it was also shown to regulate tubular phosphate, 65, 66 calcium, 67 and sodium 68 reabsorption. Aldosterone stimulates Fgf23
(mRNA) expression by osteoblasts, 69 so alternatively increased plasma aldosterone, either as the cause of or secondary to hypomagnesemia, could contribute to higher circulating FGF23.
Hypomagnesemia at diagnosis of azotemic CKD was an independent predictor of death in cats. No previous survival studies in cats with CKD assessed the effect of magnesium status, 5-7 but both hypomagnesemia and hypermagnesemia were associated with decreased survival in cats hospitalized in an intensive care unit. 70 Multiple observational studies in human CKD patients report a link between been identified as an important prognostic factor in cats with CKD.
5
Plasma FGF23 was not a significant independent predictor of survival in the analysis presented here. Adjustment for additional variables in our study and differences in grouping of variables could explain this discrepancy. Baseline FGF23 was not included in the above-mentioned survival models for humans with CKD.
The higher risk of death associated with hypermagnesemia in cats was lost after adjustment for additional variables and was possibly caused by its predominance in end-stage CKD. It must be noted that this result was based on a low number of observations, resulting in a wide 95% confidence interval.
Magnesium has been shown to suppress phosphate-induced damage to murine proximal tubular cells, 23 and to reduce the degree of renal function decline associated with hyperphosphatemia in human CKD patients. 23 Hypomagnesemia was a risk factor for progression of azotemia in our cats, but, similar to humans, 24 the association was lost in multivariable analysis. Our analysis could have been impacted by the short survival time of cats with magnesium disturbances, as demonstrating progressive increases in plasma creatinine is more difficult when the follow-up period is short. Moreover, hypomagnesemia might be a predictor for progression to end-stage disease only in humans with diabetic nephropathy, but not in patients with nondiabetic CKD. 74, 75 However, diabetes was not associated with risk of progression in another cohort of humans with CKD, 24, 75, 76 in which use of diuretics was identified as a confounder instead. None of the cats in the present study had diabetes mellitus or were administered diuretics. All mentioned models examining the relation between serum magnesium and survival in human CKD were adjusted for concurrent diabetes mellitus. [24] [25] [26] [27] [28] Although the relationship between hyperphosphatemia and renal fibrosis is well-known in cats with CKD, 8, [77] [78] [79] no evidence for a significant independent effect of plasma phosphate on progression of azotemia was found in the present study. Similar to the result from a previous study, 5 plasma FGF23 was a positive confounder for this relationship.
Moreover, the relatively low number of progressive cases might have led to insufficient statistical power to identify a significant association.
The effects of hypomagnesemia and hypermagnesemia on progression and survival might have been underestimated because of misclassification bias. Firstly, grouping of cats in different magnesium categories based on a single baseline measurement could have introduced regression dilution bias. Baseline magnesium concentration is lower in human patients that will develop hypomagnesemia during the course of their CKD, 24 but in what manner plasma magnesium changes Although multivariable analyses were performed, the possibility of residual confounding cannot be eliminated, and incomplete information Yu-Mei Chang http://orcid.org/0000-0001-6388-9626
